Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223751 | 0.72 | ALDH1A1 (0.50) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL21225218 | 0.71 | HTR2A (0.42) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL2072294 | 0.69 | KDM4E (0.50) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL29424329 | 0.69 | KDM4E (0.42) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL465036 | 0.69 | KDM4E (0.42) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL1825781 | 0.64 | HTR2A (0.46) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL15800653 | 0.62 | IDO1 (0.42) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL30569666 | 0.62 | HTR2A (0.57) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL10019851 | 0.62 | HTR2A (0.57) | KDM4ENR2E1HTR5ANISCHALDH1A1 | |
| SCHEMBL1120971 | 0.62 | HTR2A (0.57) | KDM4ENR2E1HTR5ANISCHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275576-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| US-7569567-B2 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080255129-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | US | disclosed |
| US-20080249098-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | US | disclosed |
| US-7405306-B2 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-07-29 | — | — | US | disclosed |
| US-7402682-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2008-07-22 | — | — | US | disclosed |
| US-20080076775-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-03-27 | — | — | US | disclosed |
| US-7323467-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2007-09-20 | — | — | US | disclosed |
| US-7235554-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI-AVENTIS (FR) | 2007-06-26 | — | — | US | disclosed |
| EP-1458721-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2006-11-22 | — | — | EP | disclosed |
| US-20060241116-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7109194-B2 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI-AVENTIS (FR) | 2006-09-19 | — | — | US | disclosed |
| EP-1492792-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO¬4,5-B|INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | EP | disclosed |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI (FR) | 2005-06-09 | — | — | US | disclosed |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI (FR) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076775-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | KDM4E 1207/4885NR2E1 2199/4885HTR5A 43/4885 |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | HRH4, IDO1, HTR4 | KDM4E 3162/4885NR2E1 3400/4885HTR5A 23/4885 |
| US-20060241116-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | HTR3C, TPH1, IDO1 | KDM4E 2744/4885NR2E1 2398/4885HTR5A 28/4885 |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | HTR3C, CYP3A43, IDO1 | KDM4E 2487/4885NR2E1 2735/4885HTR5A 27/4885 |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | KDM4E 975/4885NR2E1 2165/4885HTR5A 35/4885 |
| US-20090275576-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | HTR3C, TPH1, IDO1 | KDM4E 2744/4885NR2E1 2398/4885HTR5A 28/4885 |
| US-20080249098-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use | HTR3C, TPH1, IDO1 | KDM4E 2744/4885NR2E1 2398/4885HTR5A 28/4885 |
| US-20080255129-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | KDM4E 1207/4885NR2E1 2199/4885HTR5A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.